Topiramate in Migraine Prevention: A 2016 Perspective

Area of Science:

• Neurology
• Pharmacology

Background:

• Topiramate evolved from a third-tier agent to a first-line migraine preventive based on robust clinical trial data.
• Its efficacy is attributed to multiple molecular targets, differentiating it from specific anticonvulsants.
• Initial recommendations were based on expert opinion, but later guidelines incorporated evidence from randomized controlled trials.

Purpose of the Study:

• To review the established profile of topiramate in migraine prophylaxis over the last decade.
• To discuss the rationale and benefits of extended-release (XR) formulations for optimizing topiramate therapy.

Main Methods:

• Review of randomized controlled trials, meta-analyses, patient registries, cohort studies, and claims data.
• Analysis of pharmacokinetic profiles and clinical outcomes associated with immediate-release (IR) and extended-release (XR) topiramate formulations.
• Evaluation of patient-reported side effects and treatment discontinuation rates.

Main Results:

• Topiramate significantly reduces migraine frequency, acute medication use, and disability in episodic and chronic migraine.
• While paresthesia is common, cognitive side effects are less frequent but can lead to discontinuation.
• Extended-release (XR) topiramate demonstrated potentially fewer cognitive effects and improved adherence compared to immediate-release (IR) formulations.

Conclusions:

• Topiramate is effective for migraine prophylaxis, with XR formulations potentially enhancing tolerability and adherence.
• Clinicians should counsel patients on hydration and monitor for adverse events, including rare ocular complications and risks during pregnancy.
• Further research is needed to clarify topiramate's role in preventing the progression from episodic to chronic migraine.